CORTICOSTEROID-THERAPY AND BONE MASS - COMPARISON OF RHEUMATOID-ARTHRITIS AND SYSTEMIC LUPUS-ERYTHEMATOSUS

This study was designed to evaluate the effects of low-dose corticoste roid (CS) therapy for rheumatoid arthritis (RA) and of high-dose CS th erapy for systemic lupus erythematosus (SLE) on metacarpal bone mass i n young (premenopausal) subjects. Ninety-eight patients with RA, 63 pa tients with SLE and 85 healthy controls of comparable age, race, sex a nd nutritional status were studied. Metacarpal bone mass was measured by radiogrammetry using a digitiser. In the RA patients, mean bone mas s of CS-treated subjects (27%) was 52,31 g/cm(2), while that of untrea ted subjects was 56,69 g/cm(2) (P < 0,02). In the SLE group, mean bone mass of CS-treated subjects (76%) was 61,47 g/cm(2) and that of untre ated subjects 62,36 g/cm(2) (P > 0,1). Although patients with SLE requ ired larger cumulative doses bf CS for longer periods, their bone mass was higher than that of the RA subjects (P < 0,01). None of the patie nts had femoral neck or vertebral crush fractures. In RA, bone loss wa s probably a feature of severe disease rather than of CS therapy.